Visualitza per autor "Bardia, Aditya"
Ara mostrant els elements 1-6 d 6
-
Antibody–drug conjugates: smart chemotherapy delivery across tumor histologies
Tarantino, Paolo; Carmagnani Pestana, Roberto; Corti, Chiara; Modi, Shanu; Bardia, Aditya; Tolaney, Sara M; Cortés Castan, Javier (Wiley, 2022-03) -
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Bardia, Aditya; Tolaney, Sara M; Punie, Kevin; Loirat, Delphine; Antunes de Melo Oliveira, Ana Mafalda; Kalinsky, K. (Elsevier, 2021-09) -
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
Carey, Lisa; Loirat, Delphine; Punie, Kevin; Bardia, Aditya; Dieras, Veronique; Dalenc, Florence; Cortés Castan, Javier (Nature Research, 2022-06-09) -
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Rugo, Hope; Bardia, Aditya; Marmé, Frederik; Cortés Castan, Javier; Schmid, Peter; Loirat, Delphine; Gómez Pardo, Patricia (American Society of Clinical Oncology, 2022-10-10) -
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
Rugo, Hope; Tolaney, Sara M; Loirat, Delphine; Punie, Kevin; Bardia, Aditya; Hurvitz, Sara; Cortés Castan, Javier (Breast Cancer Research Foundation, 2022-08-29) -
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer
Rugo, Hope; Bardia, Aditya; Tolaney, Sara M; Arteaga, Carlos; Cortés Castan, Javier; Sohn, Joohyuk (Future Medicine, 2020-04)